Dipip Powder Sachet 15mg-120mg 16’s
Dipip Powder Sachet 15mg-120mg 16’s has the fastest action on malarial parasite among all artemisinin derivatives by rapidly eliminating blood schizonts and also have a strong effect on early and late trophozoites. Dihydroartemisinin concentrates selectively into cells contracted by parasites and reacts with heam to kill the parasites. This reaction produces poisonous free radicals that can destroy the membranes of parasites. Piperaquine, a derivative of the 4-aminoquinoline group, has a strong action on blood schizonts and late trophozoites. Piperaquine inhibits the hemozoin formation and interacts with the heam to form a ferriprotoporphyrin-piperaquine complex (FP-Piperaquine complex) which is highly toxic and damages the membrane of all types of malarial parasites and destroy them effectively. Both Dihydroartemisinin and Piperaquine also have a strong action on gametocytes which help to prevent malaria transmission.
In several patients treated with Dihydroartemisinin+Piperaquine Phosphate, no severe adverse effects have been reported. Adverse effects seen are usually light and disappear when the treatment is stopped. The common side effects are nausea, vomiting, stomachache, diarrhea, headache, dizziness itching pruritus, etc. Limited data is available to use the Dihydroartemisinin+Piperaquine Phosphate during the first
trimester. Findings of routine examination were normal, apart from the low birth-weight. However, precautions are very necessary during the first trimester. In the second & third trimesters WHO recommends the use of ACTs including Dihydroartemisinin+Piperaquine Phosphate to treat malaria.
Dipip Powder Sachet is a drug that can be used for the prophylaxis (prevention) and treatment of malaria.
Dipip Powder Sachet may cause Abdominal pain (stomach pain), Anorexia (eating disorder), diarrhea, vomiting, nausea, palpitation, and dizziness.
When Not To Use
This medicine should not be taken in patients who have a history of arrhythmia or bradycardia (heart rhythm abnormality); congestive heart failure with reduced ventricular ejection. (Less blood is pumped by the heart)